BackgroundTranscatheter aortic valve implantation (TAVI) is a well‐established intervention for severe aortic valve stenosis. However, its application for severe aortic regurgitation (AR) is still under evaluation. This study aims to present the 3‐year follow‐up outcomes of the J‐Valve system in managing severe AR.AimsThe aim of this study was to evaluate the mid‐term efficacy and durability of the J‐Valve system in the treatment of severe AR and to provide new information on this intervention.MethodsIn this retrospective, single‐center study, we evaluated the prognostic outcomes of patients with AR, who underwent treatment with the J‐Valve system at Nanjing Drum Tower Hospital. Consecutive patients who were treated with the J‐Valve were included in the analysis. The study focused on the echocardiographic follow‐up to assess the effectiveness and durability of the J‐Valve system in managing AR.ResultsFrom January 2018 to December 2022, 36 high‐risk AR patients treated with the J‐Valve system had a procedural success rate of 97.2%, with one case requiring open‐heart surgery due to valve displacement. Significant improvements were observed in left ventricular diameter (from 63.50 [58.75–69.50] mm to 56.50 [53.00–60.50] mm, p < 0.001) and left atrial diameter (from 44.00 [40.00–45.25] mm to 39.00 [36.75–41.00] mm, p = 0.003) postsurgery. All patients completed the 1‐year follow‐up, with an overall mortality rate of 2 out of 36 (5.6%). Among the surviving patients, there was one case of III° atrioventricular block and one case of stroke, both occurring within 90 days postsurgery. After a 3‐year follow‐up, 15.0% of patients had mild or moderate valvular regurgitation, with no cases of moderate or severe paravalvular leak. Additionally, 89.5% of patients were classified as New York Heart Association class I or II, showing significantly enhanced cardiac function.ConclusionThe J‐Valve system has shown positive therapeutic outcomes in treating AR, with notable effectiveness in managing the condition and significant improvements in heart failure symptoms and cardiac remodeling. However, due to the limited sample size and partial follow‐up data, it is important to emphasize the need for further research with comprehensive long‐term follow‐up, to fully validate these results.

中文翻译：

---

使用 J-Valve 系统经导管主动脉瓣植入治疗严重主动脉瓣反流：中期随访研究


背景经导管主动脉瓣植入术（TAVI）是治疗严重主动脉瓣狭窄的一种行之有效的干预措施。然而，其在严重主动脉瓣反流（AR）中的应用仍在评估中。本研究旨在呈现 J-Valve 系统治疗严重 AR 的 3 年随访结果。目的本研究的目的是评估 J-Valve 系统在治疗严重 AR 中的中期疗效和持久性方法在这项回顾性单中心研究中，我们评估了在南京鼓楼医院接受 J-Valve 系统治疗的 AR 患者的预后结果。分析中纳入了连续接受 J 瓣膜治疗的患者。该研究的重点是超声心动图随访，以评估 J-Valve 系统治疗 AR 的有效性和持久性。结果从 2018 年 1 月到 2022 年 12 月，36 名接受 J-Valve 系统治疗的高危 AR 患者的手术成功率97.2%，其中 1 例因瓣膜移位需要进行心脏直视手术。左心室直径（从 63.50 [58.75–69.50] mm 到 56.50 [53.00–60.50] mm，p < 0.001）和左心房直径（从 44.00 [40.00–45.25] mm 到 39.00 [36.75–41.00] 显着改善] 毫米，p = 0.003) 术后。所有患者均完成了 1 年随访，总死亡率为 36 例中有 2 例（5.6%）。存活患者中，有1例III°房室传导阻滞和1例中风，均发生在术后90天内。 3年随访后，15.0%的患者出现轻度或中度瓣膜反流，无中度或重度瓣周漏病例。另外，89。5% 的患者被归类为纽约心脏协会 I 级或 II 级，显示出心功能显着增强。结论 J-Valve 系统在治疗 AR 方面显示出积极的治疗效果，在控制病情方面效果显着，并显着改善心力衰竭症状和心脏重塑。然而，由于样本量有限且随访数据不完整，需要强调需要进一步研究和全面的长期随访，以充分验证这些结果。